Equity · Healthcare
KALV
NGMKalVista Pharmaceuticals (KALV)
This price chart is drawn by TradingView, from their own data, in an embed loaded from their servers. We hold too few licensed daily closes of our own for KALV to draw a line in its place.
Have KalVista Pharmaceuticals (KALV) insiders bought or sold shares recently?
KALV has no Form 4 filing in the last 90 days, so there is no summary for that window. The most recent filings we hold are below, the newest dated 11 June 2026.
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 27 May 2026 | Yea ChristopherCHIEF DEVELOPMENT OFFICER | Sell | 33,800 | 905K USD |
| 26 May 2026 | Audhya Paul K.CHIEF MEDICAL OFFICER | Sell | 2,239 | 60K USD |
| 26 May 2026 | Yea ChristopherCHIEF DEVELOPMENT OFFICER | Sell | 1,966 | 53K USD |
| 26 May 2026 | Sweeny NicoleChief Commercial Officer | Sell | 1,489 | 40K USD |
| 22 May 2026 | Audhya Paul K.CHIEF MEDICAL OFFICER | Sell | 2,685 | 72K USD |
| 22 May 2026 | Palleiko Benjamin LCHIEF EXECUTIVE OFFICER | Sell | 10,926 | 293K USD |
| 22 May 2026 | Yea ChristopherCHIEF DEVELOPMENT OFFICER | Sell | 2,358 | 63K USD |
| 22 May 2026 | Piekos BrianChief Financial Officer | Sell | 1,489 | 40K USD |
| 22 May 2026 | Sweeny NicoleChief Commercial Officer | Sell | 1,861 | 50K USD |
| 18 May 2026 | Audhya Paul K.CHIEF MEDICAL OFFICER | Sell | 1,032 | 28K USD |
| 18 May 2026 | Palleiko Benjamin LCHIEF EXECUTIVE OFFICER | Sell | 1,129 | 30K USD |
| 18 May 2026 | Yea ChristopherCHIEF DEVELOPMENT OFFICER | Sell | 1,108 | 30K USD |
| Sold | 39 open-market sales | 384,526 | $7.07M |
Showing the 12 most recent of 39 open-market trades in this window. The figures above count all of them.
56 other filings: grants, exercises, tax withholding and transfers, not trades
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 11 Jun 2026 | Audhya Paul K.CHIEF MEDICAL OFFICER | Other | 150,260 | |
| 11 Jun 2026 | Palleiko Benjamin LCHIEF EXECUTIVE OFFICER | Other | 479,989 | |
| 11 Jun 2026 | Yea ChristopherCHIEF DEVELOPMENT OFFICER | Other | 229,918 | |
| 11 Jun 2026 | Piekos BrianChief Financial Officer | Other | 21,661 | |
| 11 Jun 2026 | Sweeny NicoleChief Commercial Officer | Other | 59,291 | |
| 27 May 2026 | Yea ChristopherCHIEF DEVELOPMENT OFFICER | Option exercise | 33,800 | 239K USD |
| 22 May 2026 | Audhya Paul K.CHIEF MEDICAL OFFICER | Option exercise | 5,000 | |
| 22 May 2026 | Yea ChristopherCHIEF DEVELOPMENT OFFICER | Option exercise | 3,125 | |
| 22 May 2026 | Sweeny NicoleChief Commercial Officer | Option exercise | 5,000 | |
| 21 May 2026 | Audhya Paul K.CHIEF MEDICAL OFFICER | Option exercise | 6,250 | |
| 21 May 2026 | Palleiko Benjamin LCHIEF EXECUTIVE OFFICER | Option exercise | 23,250 | |
| 21 May 2026 | Yea ChristopherCHIEF DEVELOPMENT OFFICER | Option exercise | 3,750 |
Showing the 12 most recent of 56 compensation filings in this window. The figures above count all of them.
Which funds hold KalVista Pharmaceuticals (KALV)?
0 of the 45 institutional funds we track reported a KalVista Pharmaceuticals position for the quarter ended 30 Jun 2026; the latest of those filings landed 02 Sep 2026.
| Fund | Position | Shares | Value | Shares q/q |
|---|---|---|---|---|
| AQR Capital Management | Exited | |||
| Balyasny Asset Management | Exited | |||
| Citadel Advisors | Exited | |||
| Man Group | Exited | |||
| Marshall Wace | Exited | |||
| Millennium Management | Exited | |||
| Point72 Asset Management | Exited | |||
| Two Sigma Investments | Exited |
Have members of Congress traded KalVista Pharmaceuticals (KALV)?
The most recent congressional trade disclosed in KalVista Pharmaceuticals is a purchase by Sara Jacobs (house, CA), dated 12 Dec 2022.
STOCK Act disclosures
| Traded | Member | Type | Amount | Filed after |
|---|---|---|---|---|
| 12 Dec 2022 | Sara Jacobshouse · Democrat–CA | Purchase | 1K USD–15K USD | 39 days |
What has been filed or recorded for KalVista Pharmaceuticals (KALV)?
The filings we hold for KalVista Pharmaceuticals, newest first: 5 quarterly earnings reports and 3 annual reports, the latest dated 31 Mar 2026. No next earnings date is announced in SEC filings yet.
| And | ||||
|---|---|---|---|---|
| 31 Mar 2026 | Quarterly earnings | Q1 2026 reported | EPS −0.43 USD | |
| 31 Dec 2025 | Annual report | FY 2025 reported | EPS −2.03 USD | |
| 30 Sep 2025 | Quarterly earnings | Q3 2025 reported | EPS −0.92 USD | Revenue $14M |
| 31 Jul 2025 | Quarterly earnings | Q1 2026 reported | EPS −1.12 USD | Revenue $1M |
| 30 Apr 2025 | Annual report | FY 2025 reported | EPS −3.69 USD | |
| 31 Mar 2025 | Quarterly earnings | Q1 2026 reported | EPS −0.98 USD | |
| 31 Jan 2025 | Quarterly earnings | Q3 2025 reported | EPS −0.92 USD | |
| 31 Dec 2024 | Annual report | FY 2025 reported | EPS −2.30 USD |
KalVista Pharmaceuticals (KALV): frequently asked questions
Have KalVista Pharmaceuticals insiders bought or sold shares recently?
No KalVista Pharmaceuticals insider has filed a Form 4 in the last 90 days; the most recent filing we hold is dated 11 Jun 2026 (SEC Form 4). See Insiders
Which funds own KalVista Pharmaceuticals?
0 of the 45 funds we track reported a KalVista Pharmaceuticals position for the quarter ended 30 Jun 2026, per their SEC Form 13F filings. The largest reported positions were AQR Capital Management, Balyasny Asset Management and Citadel Advisors. See Funds
Have members of Congress traded KalVista Pharmaceuticals?
Yes. 1 trade in KalVista Pharmaceuticals appears in the congressional disclosures we hold: a purchase by Sara Jacobs (House, CA) dated 12 Dec 2022, filed 20 Jan 2023. Amounts are disclosed as ranges, and a filing can follow the trade by up to 45 days. See Congress
When did KalVista Pharmaceuticals last report earnings?
KalVista Pharmaceuticals last reported earnings on 31 Mar 2026 for Q1 2026, with EPS of −0.43 USD; no next date is announced in SEC filings yet. See Filings
Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.
References
- TradingViewthe price chart widget, drawn by TradingView from their own data
- SEC EDGARForm 4 filings (insider transactions)
- SEC EDGAR13F filings
- House disclosuresU.S. House of Representatives financial disclosures
- SEC EDGARXBRL company facts
- SEC EDGARreported earnings figures and scheduled report dates